Literature DB >> 6440790

Stereoselective disposition of RS-tocainide in man.

K J Hoffmann, L Renberg, C Bäärnhielm.   

Abstract

The disposition of RS-tocainide in three healthy volunteers has been studied after oral administration of a pseudoracemic mixture containing S(+) [3H] tocainide as a radioactive tracer together with a therapeutic dose of the racemate. Analytical methods based on HPLC have been developed to measure S(+) and R(-) tocainide in urine samples. Selected ion detection has been used for quantification of a tocainide conjugate. The radioactive dose was efficiently absorbed and mainly cleared via the kidneys. The elimination half-life of RS-tocainide was found to be 14.3 hours. The elimination half-lives of the two stereoisomers of tocainide differed significantly, i.e. R(-) tocainide 10 hours, and S(+) tocainide 16.7 hours. The observed t1/2 for the tocainide conjugate of 10.3 hours was close to that of R(-) tocainide, indicating that the metabolite was preferably formed from the R(-) stereoisomer of tocainide. Of the given dose, between 45 and 70% can be accounted for.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440790     DOI: 10.1007/BF03189644

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  Efficacy of a new oral agent (tocainide) in the acute treatment of refractory ventricular arrhythmias.

Authors:  W Ryan; R Engler; M LeWinter; J S Karliner
Journal:  Am J Cardiol       Date:  1979-02       Impact factor: 2.778

2.  Liquid chromatography in the monitoring of plasma levels of antiarrhythmic drugs.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1978-02-11

3.  Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction.

Authors:  C Graffner; T B Conradson; S Hofvendahl; L Rydén
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

4.  Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.

Authors:  D Lalka; M B Meyer; B R Duce; A T Elvin
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

5.  Electrocardiographic and hemodynamic effects of tocainide (W-36095) in man.

Authors:  K Swedberg; J Pehrson; L Rydén
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

6.  Species differences in the urinary excretion of the novel primary amine conjugate: tocainide carbamoyl O-beta-D-glucuronide.

Authors:  K J Gipple; K T Chan; A T Elvin; D Lalka; J E Axelson
Journal:  J Pharm Sci       Date:  1982-09       Impact factor: 3.534

7.  3-(2,6-Xylyl)-5-methylhydantoin--a metabolite or a metabonate of tocainide in rats.

Authors:  R Venkataramanan; J E Axelson
Journal:  Xenobiotica       Date:  1981-04       Impact factor: 1.908

8.  Tocainide conjugation in humans: novel biotransformation pathway for a primary amine.

Authors:  A T Elvin; J B Keenaghan; E W Byrnes; P A Tenthorey; P D McMaster; B H Takman; D Lalka; C V Manion; D T Baer; E M Wolshin; M B Meyer; R A Ronfeld
Journal:  J Pharm Sci       Date:  1980-01       Impact factor: 3.534

9.  Analytical controls in drug metabolic studies. II. Artifact formation during chloroform extraction of drugs and metabolites with amine substituents.

Authors:  E J Cone; W F Buchwald; W D Darwin
Journal:  Drug Metab Dispos       Date:  1982 Nov-Dec       Impact factor: 3.922

10.  On the kinetics and dynamics of tocainide and its metabolites.

Authors:  R A Ronfeld; E M Wolshin; A J Block
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

View more
  3 in total

Review 1.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

2.  Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects.

Authors:  K M McErlane; J Axelson; R Vaughan; C R Kerr; J D Price; L Igwemezie; G Pillai
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Stereoselective disposition of mexiletine in man.

Authors:  O Grech-Belanger; J Turgeon; M Gilbert
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.